Developer docs
API playgroundTry for free, no card

Search company profiles

Martindale Pharma

Full company profile

uuid002nzgz

Namestring
Martindale Pharma
Company typeenum
Private
Founded yearint
1972
Short descriptiontext

Martindale Pharma is a UK-based international specialty pharmaceutical company, founded in 1972 and headquartered in Brentwood, operating as a subsidiary of the Ethypharm Group with 501-1,000 employees.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
501–1,000
akta.pro rankint
HeadquartersBrentwood, United Kingdom
HQ citystring
Brentwood
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Keyword5 values
specialty pharmaceuticals, prescription medicines, generic drug manufacturing, pharmaceutical distribution, pharmaceutical products
Industry1 code
PRIMARYHLAIAAAB
Specialty Care Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
NAICS code1 code
  • Pharmaceutical Preparation Manufacturing325412
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Specialty Pharmaceuticals
Social media profiles1 record
Cost components6 values
Personnel, Supply Chain, Operations, Technology or R&D, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Martindale Pharma is an international specialty pharmaceutical company that develops, manufactures, and distributes pharmaceutical products. Operating as part of the Ethypharm Group, the company serves healthcare markets with specialty medicines, and in 2016 expanded through the acquisition of Viridian Pharma.

Differentiator
Functional benefit
Problem solved
Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Martindale Pharma is identified as part of the Ethypharm Group Company. The company website domain martindalepharma.co.uk references Ethypharm in related search topics, indicating a parent-subsidiary or group company relationship. The domain is currently parked, suggesting the company may operate under the Ethypharm brand or has been integrated into the parent company.

Peers10 records
TypeRegional player
Description

UK-listed specialty pharma company focused on allergy immunotherapy and specialty therapeutics. Comparable as a UK-headquartered specialty pharma operator of similar institutional and NHS-facing commercial profile.

TypeDirect peer
Description

South African-headquartered specialty and generic pharma group with international operations including the UK and Europe. Comparable as an international specialty pharma platform of similar scale and therapeutic breadth.

TypeDirect peer
Description

UK-listed specialty pharma services and medicines company with operations across unlicensed medicines, clinical trial supply, and specialty pharma distribution. Comparable as a UK-headquartered specialty pharma platform operating in adjacent institutional and specialty channels.

TypeBroad incumbent
Description

US-headquartered specialty pharma with significant injectable and hospital-focused product portfolios. Comparable as a specialty pharma incumbent operating in similar institutional and hospital channels with overlapping therapeutic coverage in injectables and specialty categories.

TypeDirect peer
Description

Parent company and French-headquartered specialty pharma operator focused on injectable and central nervous system products. Directly comparable as the operating group of which Martindale Pharma is a subsidiary, with overlapping specialty pharma capabilities and shared therapeutic focus areas.

6Endo International
TypeBroad incumbent
Description

Specialty pharma company with portfolios in branded specialty therapeutics and injectables. Comparable as an institutional-channel specialty pharma operator with overlapping regulatory and commercial dynamics to Martindale.

TypeDirect peer
Description

US-based specialty and generic pharmaceutical company with a meaningful injectables and specialty franchise. Comparable as a mid-sized specialty pharma with hospital/institutional channel exposure and injectable focus.

TypeDirect peer
Description

UK-listed specialty and generic pharmaceutical company with a strong injectables franchise across the US, MENA, and Europe. Highly comparable to Martindale in therapeutic focus on injectable specialty products and UK-headquartered specialty pharma scale.

TypeDirect peer
Description

UK and Ireland-based specialty pharma company commercializing branded specialty products in women's health, neurology, and specialty categories. Highly comparable as a UK-headquartered specialty pharma of similar scale.

TypeDirect peer
Description

Specialty and generic pharma operator with portfolios in injectables and specialty hospital products. Comparable in scale, therapeutic mix, and institutional-channel exposure to Martindale Pharma's specialty focus.

Market position
Customer concentration

Classification, Details

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Martindale Pharma

Specialty Pharmaceuticalsmartindalepharma.co.uk

Martindale Pharma is a UK-based international specialty pharmaceutical company, founded in 1972 and headquartered in Brentwood, operating as a subsidiary of the Ethypharm Group with 501-1,000 employees.

Martindale Pharma firmographics

Firmographics
Name
Martindale Pharma
Website
https://martindalepharma.co.uk
Company type
Private
Founded year
1972
Operating status
Operating
Headcount range
501–1,000 employees
Short description
Martindale Pharma is a UK-based international specialty pharmaceutical company, founded in 1972 and headquartered in Brentwood, operating as a subsidiary of the Ethypharm Group with 501-1,000 employees.
Ownership category
akta.pro rank

Martindale Pharma industry classification

Industry
Product category
Specialty Pharmaceuticals
NAICS
Pharmaceutical Preparation Manufacturing (325412)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIAAAB
Specialty Care Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

Keywords

  • Specialty pharmaceuticals
  • Prescription medicines
  • Generic drug manufacturing
  • Pharmaceutical distribution
  • Pharmaceutical products

Where Martindale Pharma is headquartered

Location

Headquarters

HQ city
Brentwood
HQ country
United Kingdom
HQ region
Europe

Markets served

Martindale Pharma business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Supply Chain, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Martindale Pharma product offering

Product offering

Core offering

Martindale Pharma is an international specialty pharmaceutical company that develops, manufactures, and distributes pharmaceutical products. Operating as part of the Ethypharm Group, the company serves healthcare markets with specialty medicines, and in 2016 expanded through the acquisition of Viridian Pharma.

Differentiator

Problem solved

Functional benefit

Companies that use Martindale Pharma

Customer profile

Ideal customer profiles1 record

Martindale Pharma technology and API

Technology

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Martindale Pharma partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Ethypharm Group CompanycoreStrategic or Co-development PartnerMartindale Pharma is identified as part of the Ethypharm Group Company. The company website domain martindalepharma.co.uk references Ethypharm in related search topics, indicating a parent-subsidiary or group company relationship. The domain is currently parked, suggesting the company may operate under the Ethypharm brand or has been integrated into the parent company.

Martindale Pharma competitors and assessment

Company assessment

Regional players

  • Allergy Therapeutics: UK-listed specialty pharma company focused on allergy immunotherapy and specialty therapeutics. Comparable as a UK-headquartered specialty pharma operator of similar institutional and NHS-facing commercial profile.

Direct peers

  • Aspen Pharmacare: South African-headquartered specialty and generic pharma group with international operations including the UK and Europe. Comparable as an international specialty pharma platform of similar scale and therapeutic breadth.
  • Clinigen Group: UK-listed specialty pharma services and medicines company with operations across unlicensed medicines, clinical trial supply, and specialty pharma distribution. Comparable as a UK-headquartered specialty pharma platform operating in adjacent institutional and specialty channels.
  • Ethypharm Group: Parent company and French-headquartered specialty pharma operator focused on injectable and central nervous system products. Directly comparable as the operating group of which Martindale Pharma is a subsidiary, with overlapping specialty pharma capabilities and shared therapeutic focus areas.
  • Amneal Pharmaceuticals: US-based specialty and generic pharmaceutical company with a meaningful injectables and specialty franchise. Comparable as a mid-sized specialty pharma with hospital/institutional channel exposure and injectable focus.
  • Hikma Pharmaceuticals: UK-listed specialty and generic pharmaceutical company with a strong injectables franchise across the US, MENA, and Europe. Highly comparable to Martindale in therapeutic focus on injectable specialty products and UK-headquartered specialty pharma scale.
  • Consilient Health: UK and Ireland-based specialty pharma company commercializing branded specialty products in women's health, neurology, and specialty categories. Highly comparable as a UK-headquartered specialty pharma of similar scale.
  • Concordia International: Specialty and generic pharma operator with portfolios in injectables and specialty hospital products. Comparable in scale, therapeutic mix, and institutional-channel exposure to Martindale Pharma's specialty focus.

Broad incumbents

  • Mallinckrodt: US-headquartered specialty pharma with significant injectable and hospital-focused product portfolios. Comparable as a specialty pharma incumbent operating in similar institutional and hospital channels with overlapping therapeutic coverage in injectables and specialty categories.
  • Endo International: Specialty pharma company with portfolios in branded specialty therapeutics and injectables. Comparable as an institutional-channel specialty pharma operator with overlapping regulatory and commercial dynamics to Martindale.

Market position

Customer concentration

Martindale Pharma social profiles

Digital presence

Martindale Pharma financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Martindale Pharma leadership team

Management profile

Number of profiles

Martindale Pharma funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Martindale Pharma M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Martindale Pharma

What does Martindale Pharma do?

Martindale Pharma is an international specialty pharmaceutical company that develops, manufactures, and distributes pharmaceutical products. Operating as part of the Ethypharm Group, the company serves healthcare markets with specialty medicines, and in 2016 expanded through the acquisition of Viridian Pharma.

When was Martindale Pharma founded?

Martindale Pharma was founded in 1972. It employs 501 to 1,000 people.

Where is Martindale Pharma based?

Martindale Pharma is headquartered in Brentwood, United Kingdom, in the Europe region.

Who are Martindale Pharma's main competitors?

Allergy Therapeutics is listed as a regional player. Direct peers are Aspen Pharmacare, Clinigen Group, Ethypharm Group, Amneal Pharmaceuticals, Hikma Pharmaceuticals, Consilient Health and Concordia International. Broad incumbents are Mallinckrodt and Endo International.

Does Martindale Pharma have an API?

No public API is recorded for Martindale Pharma.

What industry is Martindale Pharma in?

Martindale Pharma's product category is Specialty Pharmaceuticals. Its primary akta.pro industry code is HLAIAAAB, Specialty Care Pharmaceuticals. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireEthypharm Acquires Martindale Pharma in the UKEthypharm announced on January 19, 2017 that it has signed a definitive agreement to acquire Martindale Pharma, a UK-based specialty pharmaceutical company. The acquisition creates a combined group with revenues exceeding €300 million, strengthening Ethypharm's manufacturing capabilities across solid dose, injectables, and oral liquids while expanding its geographic reach to over 50 countries. Martindale Pharma CEO Michael Harris will become COO of Ethypharm following the transaction.PR NewswireClobazam Oral Suspension Approved in Seven European CountriesMartindale Pharma announced regulatory approval of its clobazam oral suspension products in seven European countries: Epaclob® in France, Ireland, Germany, and Italy, and Silocalm® in Denmark, Spain, and Iceland, following a decentralized procedure. The products, based on Tapclob® (the world's first oral liquid clobazam suspension, available since May 2013), are approved in two strengths and are used as adjunctive therapy for epilepsy, particularly suitable for children and young adults. The company stated this expansion will provide prescribers and patients in these markets with a licensed, cost-effective oral liquid formulation.PR NewswireMartindale Pharma® Announces Extension of Licensing Agreement With Unimedic AB to Include Emergency Care Product PortfolioMartindale Pharma announced the extension of its licensing agreement with Unimedic AB to include Emergency Care sterile ampoule products for the Scandinavian markets of Sweden, Denmark, Norway, and Finland. Under the new agreement, Unimedic AB will launch three undisclosed products, building on the existing successful partnership where it already commercializes Martindale Pharma's adrenaline ampoule product in Sweden. The companies will collaborate on regulatory and supply chain activities leading to product launches, with Martindale Pharma planning to add additional products from its Emergency Care range in the coming months.PR NewswireMartindale Pharma Expands European Commercial Activities to Include FranceMartindale Pharma announced the approval and supply of Noyada, an oral liquid formulation of captopril for paediatric conditions, in France under an ATU de Cohorte programme starting in June. Cevidra Laboratories will distribute the product in France while Martindale initiates the process for full Marketing Authorisation Approval. This expansion marks the first time the only approved oral liquid captopril in Europe is available in the French market.PR NewswirePrenoxad Injection Approved in Five European Countries Opening Way for Pan-European Availability of a Take-home Naloxone ProductMartindale Pharma, a UK-based specialty pharmaceutical company, announced regulatory approval of Prenoxad Injection (the world's first take-home naloxone product) in Sweden, Denmark, Ireland, Finland, and Estonia following a successful decentralised procedure, marking a major step toward pan-European availability. The company also out-licensed exclusive commercial rights for France to Ethypharm, with plans to file for regulatory approval in France in summer 2016. Prenoxad Injection is designed for use by non-healthcare professionals to reverse opioid overdoses in community settings, where approximately 6,500 overdose deaths occur annually across Europe among an estimated 1.3 million people suffering from opioid addiction.PR NewswireMartindale Pharma Announces New Distribution Agreement for Ireland With FanninMartindale Pharma, a UK-based specialty pharmaceutical company, announced a new multi-year distribution and commercialization agreement with Fannin Limited, a leading pharmaceutical supplier in Ireland and subsidiary of DCC Vital. Under the agreement, Fannin will distribute Martindale's products across Emergency Care, Hospital-initiated Medicines, and Opioid Addiction portfolios throughout Ireland, building on their existing long-term relationship. The product range includes methadone, Noyada (Europe's first licensed oral liquid captopril solution), Teglutik (oral riluzole formulation), and Prenoxad Injection (naloxone for community use).PR NewswireMartindale Pharma Launches First Ready-To-Use Presentation of PhenylephrineMartindale Pharma announced the UK launch of a new ready-to-use Phenylephrine presentation (0.1mg/ml in 10ml ampoule), eliminating the need for dilution prior to administration in anesthetic procedures. The company licensed exclusive rights to this product range from Swedish partner Unimedic AB for the UK and Gulf Cooperation Council Countries, with the new formulation offering more accurate dosing, time savings, and a lower NHS price compared to the existing concentrated alternative.PR NewswireMartindale Pharma Announces Major Extension to Partnership in Saudi Arabia and Substantial New Business WinsMartindale Pharma, a UK-based specialty pharmaceutical company, announced extending its distribution partnership with Faisal Musaed El Seif Saudi Pharmaceutical Co. and receiving marketing authorizations for six products in Saudi Arabia. The company was awarded the SGH 38 tender to supply 13 products to Ministry of Health hospitals in Saudi Arabia and Gulf countries, representing a 30% increase in product lines and 70% value increase over the previous tender, with supplies starting September 2016 for 12 months. The company stated Saudi Arabia is now its largest international market and projects significant sales growth in the Middle East over the next two years.